Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.47 |
| ▸ | CTSC | P53634 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220110 | 0.93 | FKBP1A (0.53) | FKBP1ACTSCSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27475679 | 0.87 | FKBP1A (0.57) | FKBP1ACTSCSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5017072 | 0.82 | HTR2C (0.47) | CTSCSLC6A3SLC6A2SLC6A4CYP3A4 | |
| SCHEMBL3676417 | 0.82 | HTR2C (0.47) | CTSCSLC6A3SLC6A2SLC6A4CYP3A4 | |
| SCHEMBL30501727 | 0.80 | TSHR (0.55) | SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL28094618 | 0.80 | TSHR (0.55) | SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL16586222 | 0.79 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL5016287 | 0.79 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL22861529 | 0.78 | FKBP1A (0.50) | FKBP1A | |
| SCHEMBL25756614 | 0.78 | FKBP1A (0.50) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754176-B1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMA (US) | 2001-12-05 | — | — | EP | claimed |
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090291964-A1 | Potentiators of Antibacterial Activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-26 | — | — | US | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| WO-2005007162-A1 | COMPOUNDS AUGMENTING THE ACTIVITY OF ANTIBACTERIAL AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291964-A1 | Potentiators of Antibacterial Activity | SLC11A2, MPO, ABCB11 | FKBP1A 1960/4885CTSC 167/4885SLC6A3 1778/4885 |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | FKBP1A 2885/4885CTSC 34/4885SLC6A3 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.